Publications by authors named "Lior Kroeze"
Background And Objectives: It is unclear to what extent cognitive outcome measures are sensitive to capture decline in Alzheimer disease (AD) prevention trials. We aimed to analyze the sensitivity to changes over time of a range of neuropsychological tests in several cognitively unimpaired, biomarker-defined patient groups.
Methods: Cognitively unimpaired individuals from the Amsterdam Dementia Cohort and the SCIENCe project with available AD biomarkers, obtained from CSF, PET scans, and plasma at baseline, were followed over time (4.
Article Synopsis
- The study focused on the impact of small vessel disease (SVD) in predicting Alzheimer's disease outcomes in non-demented individuals.
- About 39% of participants showed no signs of either SVD or amyloid beta (Aβ), while those with Aβ exhibited quicker cognitive decline.
- Though SVD alone slightly indicated increased dementia risk in participants without Aβ, it did not worsen cognitive decline in those with Aβ.
Introduction: We investigated changes in self- and study partner-reported self-perceived cognitive decline in relation to amyloid pathology and clinical progression, in a sample of cognitively normal individuals.
Methods: A total of 404 participants (63 ± 9 years, 44% female) and their study partners completed the Cognitive Change Index (CCI) yearly (0.7-6.
Background: Biomarkers for amyloid, tau, and neurodegeneration (ATN) have predictive value for clinical progression, but it is not clear how individuals move through these stages. We examined changes in ATN profiles over time, and investigated determinants of change in A status, in a sample of cognitively normal individuals presenting with subjective cognitive decline (SCD).
Methods: We included 92 individuals with SCD from the SCIENCe project with [F]florbetapir PET (A) available at two time points (65 ± 8y, 42% female, MMSE 29 ± 1, follow-up 2.